
The retrospective study analyzed 126 patients with stage IV metastatic hormone-sensitive prostate cancer (mHSPC) classified as low-volume according to CHAARTED criteria. Among the cohort, seven patients had N1M0, 28 had M1a, and 91 had M1b metastases. Five-year progression-free survival (PFS) was higher in patients with M1a metastasis (80.9%) compared to M1b (54.9%), though not statistically significant (p=0.3). High prostate-specific antigen (PSA) (≥25) emerged as an independent prognostic factor for PFS (HR=2.80, p=0.0179). Treatment preferences varied among subcategories, reflecting a lack of consensus on the optimal regimen and the emerging role of consolidation prostate radiotherapy (cRT) in clinical management. Findings highlight the need for further studies to refine prognostic stratification and treatment approaches in low-volume mHSPC.
Like
Save
Share